Morris R G, Saccoia N C, Sallustio B C, Zacest R
Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville South, Australia.
Ther Drug Monit. 1991 Jul;13(4):345-9. doi: 10.1097/00007691-199107000-00011.
An improved assay for racemic atenolol (AT) concentrations in human plasma and urine is described using a high-performance liquid chromatographic method with fluorescence detection. The method has a sensitivity limit of 0.5 micrograms/L in plasma with acceptable within- and between-run reproducibilities, and demonstrated linearity at concentrations up to 2,000 micrograms/L. A pilot clinical evaluation of the assay was undertaken on 56 trough plasma specimens from 36 outpatients on established AT therapy. Atenolol concentrations in these patients showed large variations at all prescribed doses, including undetectable levels in four patients (revealing unsuspected noncompliance). Because of its sensitivity and applicability to urinary analysis, the method can be used for pharmacokinetic studies and, under certain circumstances, may be valuable in clinical therapeutic drug monitoring.
描述了一种采用带荧光检测的高效液相色谱法测定人血浆和尿液中消旋阿替洛尔(AT)浓度的改进方法。该方法在血浆中的检测限为0.5微克/升,批内和批间重复性均可接受,在高达2000微克/升的浓度范围内呈线性。对36名接受既定AT治疗的门诊患者的56份谷值血浆样本进行了该检测方法的初步临床评估。这些患者的阿替洛尔浓度在所有规定剂量下都有很大差异,包括4名患者检测不到(显示出未被怀疑的不依从性)。由于其灵敏度和对尿液分析的适用性,该方法可用于药代动力学研究,在某些情况下,可能对临床治疗药物监测有价值。